CNS Pharmaceuticals (CNSP) Competitors $0.87 -0.03 (-3.60%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$0.90 +0.02 (+2.77%) As of 07/11/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNSP vs. NAII, BCTX, LGVN, JATT, BLRX, CING, MRKR, BIVI, QTTB, and MTEXShould you be buying CNS Pharmaceuticals stock or one of its competitors? The main competitors of CNS Pharmaceuticals include Natural Alternatives International (NAII), Briacell Therap (BCTX), Longeveron (LGVN), JATT Acquisition (JATT), BioLineRx (BLRX), Cingulate (CING), Marker Therapeutics (MRKR), BioVie (BIVI), Q32 Bio (QTTB), and Mannatech (MTEX). These companies are all part of the "pharmaceutical products" industry. CNS Pharmaceuticals vs. Its Competitors Natural Alternatives International Briacell Therap Longeveron JATT Acquisition BioLineRx Cingulate Marker Therapeutics BioVie Q32 Bio Mannatech CNS Pharmaceuticals (NASDAQ:CNSP) and Natural Alternatives International (NASDAQ:NAII) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership. Which has higher valuation & earnings, CNSP or NAII? Natural Alternatives International has higher revenue and earnings than CNS Pharmaceuticals. Natural Alternatives International is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCNS PharmaceuticalsN/AN/A-$14.86M-$3.75 thousand0.00Natural Alternatives International$113.80M0.19-$7.22M-$1.39-2.51 Do institutionals & insiders have more ownership in CNSP or NAII? 14.0% of CNS Pharmaceuticals shares are held by institutional investors. Comparatively, 32.4% of Natural Alternatives International shares are held by institutional investors. 0.1% of CNS Pharmaceuticals shares are held by insiders. Comparatively, 20.9% of Natural Alternatives International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to CNSP or NAII? In the previous week, CNS Pharmaceuticals had 1 more articles in the media than Natural Alternatives International. MarketBeat recorded 2 mentions for CNS Pharmaceuticals and 1 mentions for Natural Alternatives International. Natural Alternatives International's average media sentiment score of 1.91 beat CNS Pharmaceuticals' score of 0.62 indicating that Natural Alternatives International is being referred to more favorably in the news media. Company Overall Sentiment CNS Pharmaceuticals Positive Natural Alternatives International Very Positive Do analysts recommend CNSP or NAII? CNS Pharmaceuticals presently has a consensus target price of $25.00, indicating a potential upside of 2,757.80%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe CNS Pharmaceuticals is more favorable than Natural Alternatives International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Natural Alternatives International 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, CNSP or NAII? CNS Pharmaceuticals has a beta of 2.58, meaning that its stock price is 158% more volatile than the S&P 500. Comparatively, Natural Alternatives International has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Is CNSP or NAII more profitable? CNS Pharmaceuticals has a net margin of 0.00% compared to Natural Alternatives International's net margin of -6.56%. Natural Alternatives International's return on equity of -10.34% beat CNS Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets CNS PharmaceuticalsN/A -385.41% -193.20% Natural Alternatives International -6.56%-10.34%-5.19% SummaryNatural Alternatives International beats CNS Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get CNS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNSP vs. The Competition Export to ExcelMetricCNS PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.96M$2.96B$5.62B$9.10BDividend YieldN/A2.39%5.24%4.00%P/E Ratio0.0020.8528.1820.27Price / SalesN/A289.03428.7098.48Price / CashN/A42.8637.4658.16Price / Book0.167.638.045.49Net Income-$14.86M-$55.05M$3.19B$250.45M7 Day Performance-5.02%8.43%3.62%4.79%1 Month Performance-1.71%5.42%4.06%7.68%1 Year Performance-98.58%2.03%30.00%16.43% CNS Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNSPCNS Pharmaceuticals2.1576 of 5 stars$0.87-3.6%$25.00+2,757.8%-98.6%$4.96MN/A0.005News CoverageNAIINatural Alternatives International1.481 of 5 stars$3.32+2.2%N/A-38.8%$20.08M$113.80M-2.39290BCTXBriacell Therap1.9109 of 5 stars$2.89-0.7%$32.00+1,007.3%-85.3%$19.72MN/A-0.358News CoverageGap DownLGVNLongeveron3.5048 of 5 stars$1.29-1.5%$8.67+571.8%-63.5%$19.56M$2.39M-0.2120News CoverageJATTJATT AcquisitionN/A$1.13+0.9%N/A-61.9%$19.49MN/A0.003High Trading VolumeBLRXBioLineRx2.6526 of 5 stars$4.32-3.8%$26.00+501.9%-82.0%$19.14M$22.34M-0.4940News CoverageAnalyst UpgradeCINGCingulate3.1088 of 5 stars$4.42+3.3%$26.00+488.2%+805.5%$18.17MN/A-0.5220News CoverageMRKRMarker Therapeutics4.5298 of 5 stars$1.57-1.9%$13.17+738.6%-64.8%$18.10M$6.59M-1.1860News CoverageBIVIBioVie1.1399 of 5 stars$8.10-15.6%N/A+63.7%$17.83MN/A-1.0210News CoveragePositive NewsQTTBQ32 Bio2.7104 of 5 stars$1.36-5.6%$12.17+794.6%-88.1%$17.57M$1.16M-0.2839Gap DownMTEXMannatech1.4052 of 5 stars$8.90-3.8%N/A+20.4%$17.49M$117.87M-89.00250High Trading Volume Related Companies and Tools Related Companies NAII Competitors BCTX Competitors LGVN Competitors JATT Competitors BLRX Competitors CING Competitors MRKR Competitors BIVI Competitors QTTB Competitors MTEX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNSP) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CNS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
